{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:21:03Z","timestamp":1774981263473,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015760","name":"Inserm Transfert","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019125","name":"Sorbonne Universit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-CE17-0006-02"],"award-info":[{"award-number":["ANR-18-CE17-0006-02"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.omtn.2022.08.016","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T20:01:40Z","timestamp":1660420900000},"page":"733-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations"],"prefix":"10.1016","volume":"29","author":[{"given":"Swati","family":"Dudhal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lylia","family":"Mekzine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Prudhon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karishma","family":"Soocheta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Cadot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Mamchaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9216-6117","authenticated-orcid":false,"given":"Delphine","family":"Trochet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bitoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2022.08.016_bib1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.spen.2011.10.006","article-title":"Centronuclear myopathies","volume":"18","author":"Romero","year":"2011","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.omtn.2022.08.016_bib2","first-page":"1085","article-title":"Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations","volume":"258","author":"Hanisch","year":"2011","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtn.2022.08.016_bib3","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ana.21235","article-title":"Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset","volume":"62","author":"Bitoun","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2022.08.016_bib4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/ng1657","article-title":"Mutations in dynamin 2 cause dominant Centronuclear Myopathy","volume":"37","author":"Bitoun","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2022.08.016_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ng1514","article-title":"Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease","volume":"37","author":"Zuchner","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2022.08.016_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12883-015-0481-3","article-title":"Adult-onset autosomal dominant spastic paraplegia linked to a GTPase-effector domain mutation of dynamin 2","volume":"15","author":"Sambuughin","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.omtn.2022.08.016_bib7","first-page":"219","article-title":"Caveolin-1 and dynamin-2 overexpression is associated with the progression of bladder cancer","volume":"18","author":"Raja","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omtn.2022.08.016_bib8","doi-asserted-by":"crossref","first-page":"e924590","DOI":"10.12659\/MSM.924590","article-title":"Dynamin 2 is correlated with recurrence and poor prognosis of papillary thyroid cancer","volume":"26","author":"Ren","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.omtn.2022.08.016_bib9","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1172\/JCI87191","article-title":"Dynamin impacts homology-directed repair and breast cancer response to chemotherapy","volume":"128","author":"Chernikova","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtn.2022.08.016_bib10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/onc.2011.329","article-title":"Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma","volume":"31","author":"Eppinga","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2022.08.016_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cam4.168","article-title":"The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting","volume":"3","author":"Xu","year":"2014","journal-title":"Cancer Med."},{"key":"10.1016\/j.omtn.2022.08.016_bib12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13046-021-02045-y","article-title":"A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target","volume":"40","author":"Trochet","year":"2021","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2022.08.016_bib13","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1172\/JCI71206","article-title":"Reducing dynamin 2 expression rescues X-linked centronuclear myopathy","volume":"124","author":"Cowling","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtn.2022.08.016_bib14","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1242\/jcs.051714","article-title":"Dynamins at a glance","volume":"122","author":"Heymann","year":"2009","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omtn.2022.08.016_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrm3266","article-title":"Dynamin, a membrane-remodelling GTPase","volume":"13","author":"Ferguson","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2022.08.016_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00109-009-0587-4","article-title":"Dynamin 2 and human diseases","volume":"88","author":"Durieux","year":"2010","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.omtn.2022.08.016_bib17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/humu.22067","article-title":"Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy","volume":"33","author":"Bohm","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.08.016_bib18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/humu.21086","article-title":"Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis","volume":"30","author":"Bitoun","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.08.016_bib19","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1038\/emboj.2010.187","article-title":"Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients","volume":"29","author":"Kenniston","year":"2010","journal-title":"EMBO J."},{"key":"10.1016\/j.omtn.2022.08.016_bib20","doi-asserted-by":"crossref","first-page":"22753","DOI":"10.1074\/jbc.C110.130013","article-title":"Dynamin 2 mutants linked to centronuclear myopathies form abnormally stable polymers","volume":"285","author":"Wang","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2022.08.016_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.devcel.2009.11.005","article-title":"Coordinated actions of actin and BAR proteins upstream of dynamin at endocytic clathrin-coated pits","volume":"17","author":"Ferguson","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2022.08.016_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.15252\/emmm.201707988","article-title":"Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy","volume":"10","author":"Trochet","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2022.08.016_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/1566523215666150812115730","article-title":"Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls","volume":"15","author":"Trochet","year":"2015","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omtn.2022.08.016_bib24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2009.273","article-title":"First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder","volume":"18","author":"Leachman","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.08.016_bib25","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2022.08.016_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington\u2019s disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omtn.2022.08.016_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2199-13-6","article-title":"An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases","volume":"13","author":"Fiszer","year":"2012","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.omtn.2022.08.016_bib28","doi-asserted-by":"crossref","first-page":"21731","DOI":"10.1073\/pnas.1012153107","article-title":"Tailor-made RNAi knockdown against triplet repeat disease-causing alleles","volume":"107","author":"Takahashi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2022.08.016_bib29","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1096\/fj.201802635R","article-title":"Correlative SICM-FCM reveals changes in morphology and kinetics of endocytic pits induced by disease-associated mutations in dynamin","volume":"33","author":"Ali","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2022.08.016_bib30","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","article-title":"Identification and allele-specific silencing of the mutant huntingtin allele in Huntington\u2019s disease patient-derived fibroblasts","volume":"19","author":"van Bilsen","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2022.08.016_bib31","doi-asserted-by":"crossref","first-page":"e99341","DOI":"10.1371\/journal.pone.0099341","article-title":"Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells","volume":"9","author":"Drouet","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2022.08.016_bib32","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/ejhg.2014.39","article-title":"Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts","volume":"22","author":"Scholefield","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2022.08.016_bib33","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/j.1600-0854.2011.01250.x","article-title":"Common membrane trafficking defects of disease-associated dynamin 2 mutations","volume":"12","author":"Liu","year":"2011","journal-title":"Traffic"},{"key":"10.1016\/j.omtn.2022.08.016_bib34","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/brain\/aws061","article-title":"Dynamin 2 mutations in Charcot-Marie-Tooth neuropathy highlight the importance of clathrin-mediated endocytosis in myelination","volume":"135","author":"Sidiropoulos","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2022.08.016_bib35","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.omtn.2019.02.019","article-title":"Allele-specific CRISPR\/Cas9 correction of a heterozygous DNM2 mutation rescues centronuclear myopathy cell phenotypes","volume":"16","author":"Rabai","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2022.08.016_bib36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1091\/mbc.E19-07-0395","article-title":"Dynamin 2 interacts with \u03b1-actinin 4 to drive tumor cell invasion","volume":"31","author":"Burton","year":"2020","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omtn.2022.08.016_bib37","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3892\/ijo.2016.3592","article-title":"Actin bundling by dynamin 2 and cortactin is implicated in cell migration by stabilizing filopodia in human non-small cell lung carcinoma cells","volume":"49","author":"Yamada","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omtn.2022.08.016_bib38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2016.10.063","article-title":"Dynamin2 GTPase contributes to invadopodia formation in invasive bladder cancer cells","volume":"480","author":"Zhang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2022.08.016_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.devcel.2013.02.010","article-title":"Dynamin 2 potentiates invasive migration of pancreatic tumor cells through stabilization of the Rac1 GEF Vav1","volume":"24","author":"Razidlo","year":"2013","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2022.08.016_bib40","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1158\/0008-5472.CAN-18-3369","article-title":"A direct podocalyxin\u2013dynamin-2 interaction regulates cytoskeletal dynamics to promote migration and metastasis in pancreatic cancer cells","volume":"79","author":"Wong","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2022.08.016_bib41","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.bbrc.2013.11.118","article-title":"N\u2032-[4-(dipropylamino)benzylidene]-2-hydroxybenzohydrazide is a dynamin GTPase inhibitor that suppresses cancer cell migration and invasion by inhibiting actin polymerization","volume":"443","author":"Yamada","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2022.08.016_bib42","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1091\/mbc.e02-05-0308","article-title":"Dynamin participates in focal extracellular matrix degradation by invasive cells","volume":"14","author":"Baldassarre","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omtn.2022.08.016_bib43","doi-asserted-by":"crossref","first-page":"E1872","DOI":"10.1073\/pnas.1400749111","article-title":"Control of MT1-MMP transport by atypical PKC during breast-cancer progression","volume":"111","author":"Rosse","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2022.08.016_bib44","doi-asserted-by":"crossref","first-page":"e21346","DOI":"10.1096\/fj.202001313RRR","article-title":"Satellite cells deficiency and defective regeneration in dynamin 2-related centronuclear myopathy","volume":"35","author":"F Almeida","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2022.08.016_bib45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.nmd.2007.01.019","article-title":"Impact on oxidative phosphorylation of immortalization with the telomerase gene","volume":"17","author":"Aur\u00e9","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2022.08.016_bib46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/B978-0-12-391857-4.00009-4","article-title":"Methods for cell and particle tracking","volume":"504","author":"Meijering","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.omtn.2022.08.016_bib47","doi-asserted-by":"crossref","first-page":"e89073","DOI":"10.1371\/journal.pone.0089073","article-title":"Fast, multi-dimensional and simultaneous kymograph-like particle dynamics (SkyPad) analysis","volume":"9","author":"Cadot","year":"2014","journal-title":"PLoS One"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122002153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122002153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:35:55Z","timestamp":1761874555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253122002153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":47,"alternative-id":["S2162253122002153"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2022.08.016","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2022.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}